Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.54 |
| ▸ | TAS2R14 | Q9NYV8 | 11/20 | 0.53 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29671340 | 0.90 | APLNR (0.61) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL27020194 | 0.83 | TAS2R14 (0.59) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL31034592 | 0.83 | APLNR (0.52) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL31034596 | 0.83 | APLNR (0.52) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL31034527 | 0.82 | TAS2R14 (0.60) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL29671219 | 0.82 | APLNR (0.51) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL31034551 | 0.81 | APLNR (0.56) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL29671186 | 0.81 | APLNR (0.50) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL24472769 | 0.80 | HDAC6 (0.77) | TAS2R14CXCR3HDAC6HDAC11HDAC8 | |
| SCHEMBL29671252 | 0.80 | APLNR (0.49) | APLNRTAS2R14PTGESTAS2R8CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| EP-4247787-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 Ontario, Inc. (CA) | 2023-09-27 | — | — | EP | disclosed |
| EP-4247794-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2023-09-27 | — | — | EP | disclosed |
| CN-116745264-A | Methods and compositions for KRAS modification | 2692372安大略公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC (CA) | 2022-09-08 | — | — | US | disclosed |
| EP-4017843-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022106902-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106897-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
| CN-114502533-A | Benzenesulfonamide derivatives and use thereof | 2692372安大略公司 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | NR2E1, NR2C2, NR3C1 | APLNR 664/4885TAS2R14 2580/4885PTGES 4580/4885 |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | BCR, ARSA, VHL | APLNR 4073/4885TAS2R14 3794/4885PTGES 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.